Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases. The company's approved products include IXIARO, an inactivated Japanese encephalitis vaccine; DUKORAL, an oral cholera and enterotoxigenic E. coli vaccine; and IXCHIQ/VLA1553, a live-attenuated chikungunya vaccine. These products address specific infectious disease prevention needs across multiple geographic markets.
The company's pipeline includes several vaccine candidates in development: VLA15 for Lyme disease, S4V2 for shigellosis, VLA1601 for Zika virus, VLA1554 for human metapneumovirus, VLA84 for Clostridioides difficile infection, and VLA2112 targeting Epstein-Barr virus. Revenue streams derive from commercial sales of approved vaccines in the United States, Canada, select European markets including Germany, Austria, the Nordic countries, the United Kingdom, and France, as well as other international territories.
Valneva operates with approximately 713 full-time employees and maintains a market capitalization of approximately $1.0 billion. The company was founded in 1998 and is incorporated in France.
No 10-K filings found.